|
HY-120179-5mg
|
MedChemexpress LLC
|
LP-922761 [CAS 1454808-95-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-120179-50mg
|
MedChemexpress LLC
|
LP-922761 [CAS 1454808-95-7]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-120179-1mL
|
MedChemexpress LLC
|
LP-922761 [CAS 1454808-95-7] (10mM in DMSO)
|
|
Neuroscience-Neuromodulation
|
|
|
HY-111538-10mg
|
MedChemexpress LLC
|
MAGL-IN-1 [CAS 2324160-91-8]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-111538-100mg
|
MedChemexpress LLC
|
MAGL-IN-1 [CAS 2324160-91-8]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-111538-25mg
|
MedChemexpress LLC
|
MAGL-IN-1 [CAS 2324160-91-8]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-111538-5mg
|
MedChemexpress LLC
|
MAGL-IN-1 [CAS 2324160-91-8]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-111538-50mg
|
MedChemexpress LLC
|
MAGL-IN-1 [CAS 2324160-91-8]
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-111538-1mL
|
MedChemexpress LLC
|
MAGL-IN-1 [CAS 2324160-91-8] (10mM in DMSO)
|
|
Metabolism-sugar/lipid metabolism
|
|
|
HY-108702-10mg
|
MedChemexpress LLC
|
ML-792 [CAS 1644342-14-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108702-100mg
|
MedChemexpress LLC
|
ML-792 [CAS 1644342-14-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108702-25mg
|
MedChemexpress LLC
|
ML-792 [CAS 1644342-14-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108702-5mg
|
MedChemexpress LLC
|
ML-792 [CAS 1644342-14-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108702-50mg
|
MedChemexpress LLC
|
ML-792 [CAS 1644342-14-2]
|
|
Cancer-programmed cell death
|
|
|
HY-108702-1mL
|
MedChemexpress LLC
|
ML-792 [CAS 1644342-14-2] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
